India Glycols Demerger Moves Forward with NCLT Approval

The National Company Law Tribunal (NCLT) Allahabad Bench has accepted India Glycols Limited's second motion petition for its Scheme of Arrangement on April 9, 2026. This acceptance moves the company closer to splitting into two separate entities: Ennature Biopharma Limited and IGL Spirits Limited.

The NCLT has ordered public notices to be published in newspapers and informed relevant authorities, marking a crucial procedural step.

Why This Demerger Matters

The goal of this demerger is to create more focused businesses, which could unlock greater shareholder value. By separating operations, each entity can pursue specialized management strategies and capital allocation, leading to clearer strategic direction and improved performance for each segment.

Background and Shareholder Support

India Glycols' shareholders and unsecured creditors had already unanimously approved the demerger scheme on March 24, 2026. The NCLT Allahabad Bench had previously approved the first motion application for the scheme on January 15, 2026. The company is looking to capitalize on the growth potential of its bio-pharma and spirits & biofuel businesses by establishing them as independent, publicly traded companies.

What Changes for Investors

Shareholders will eventually hold stakes in three separate companies: the remaining India Glycols, Ennature Biopharma, and IGL Spirits. Each new entity will have its own management, strategic priorities, and may attract different types of investors. This separation is designed to allow for more targeted growth and capital investment strategies tailored to each sector's specific market conditions. Separate listings for Ennature Biopharma and IGL Spirits could also lead to distinct market valuations.

Potential Risks Ahead

The demerger still requires final regulatory and other approvals from various authorities. These authorities have 30 days from receiving notice to raise objections or request further information, which could introduce delays or new requirements. India Glycols is also managing existing legal and tax matters, including civil disputes, tax appeals, and customs duty issues, which present ongoing risks. Furthermore, the company has faced scrutiny over past financial performance, including sales growth and return on equity, alongside analyst concerns about valuation.

Peer and Market Context

Demergers are a proven strategy for unlocking value, with examples seen in companies like Piramal Enterprises (which separated its pharma business), Vedanta, and Jubilant Life Sciences. India Glycols' various segments compete in distinct markets: its chemical operations are up against players like Deepak Nitrite and Tata Chemicals; its spirits business vies with United Spirits; and its biopharma interests face competition from companies such as Biocon.

Next Steps to Watch

Key upcoming milestones include the publication of public notices in newspapers such as Business Standard and Amar Ujala. Statutory authorities will submit their responses within the 30-day period. The NCLT has scheduled the next hearing for May 21, 2026, and final approval will depend on the satisfactory resolution of any objections raised after this second motion.